Literature DB >> 15276023

Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells.

Junko Hiroki1, Hiroaki Shimokawa, Midoriko Higashi, Keiko Morikawa, Tadashi Kandabashi, Natsumi Kawamura, Toru Kubota, Toshihiro Ichiki, Mutsuki Amano, Kozo Kaibuchi, Akira Takeshita.   

Abstract

Recent studies have demonstrated that upregulated Rho-kinase plays an important role in the pathogenesis of arteriosclerosis and vasospasm in both animals and humans. However, little is known about the molecular mechanism(s) involved in the Rho-kinase upregulation. Since inflammatory mechanisms have been implicated in the pathogenesis of arteriosclerosis and vasospasm, we examined whether inflammatory stimuli upregulate Rho-kinase in vitro and in vivo. In cultured human coronary vascular smooth muscle cells (hcVSMC), inflammatory stimuli, such as angiotensin II and interleukin-1beta, increased Rho-kinase expression (at both mRNA and protein levels) and function (as evaluated by the extent of the phosphorylation of the ERM (the ezrin/radixin/moesin) family, substrates of Rho-kinase) in a time- and concentration-dependent manner. The expression of Rho-kinase was inhibited by blockades of protein kinase C (PKC) (by either GF109253 or prolonged treatment with phorbol myristate acetate for 24 h) and an adenovirus-mediated gene transfer of dominant-active Ikappa-B, suggesting an involvement of PKC and NF-kappaB in the intracellular signal transduction pathway for the Rho-kinase expression. Furthermore, coronary vascular lesion formation (characterized by medial thickening and perivascular fibrosis) induced by a long-term administration of angiotensin II was markedly suppressed in NF-kappaB(-/-) mice with reduced expression and activity of Rho-kinase in vivo. These results indicate that the expression and function of Rho-kinase are upregulated by inflammatory stimuli (e.g. angiotensin II and IL-1beta) in hcVSMC with an involvement of PKC and NF-kappaB both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276023     DOI: 10.1016/j.yjmcc.2004.05.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  38 in total

1.  Effect of Rho-kinase Inhibitor, Y27632, on Porcine Corneal Endothelial Cell Culture, Inflammation and Immune Regulation.

Authors:  Whayoung Lee; Yuko Miyagawa; Cassandra Long; Matthew Zhang; David K C Cooper; Hidetaka Hara
Journal:  Ocul Immunol Inflamm       Date:  2015-10-16       Impact factor: 3.070

2.  Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Authors:  Hiroshi Fujita; Yoshihiro Fukumoto; Kenya Saji; Koichiro Sugimura; Jun Demachi; Jun Nawata; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

3.  Increased Rho kinase activity in a Taiwanese population with metabolic syndrome.

Authors:  Ping-Yen Liu; Jyh-Hong Chen; Li-Jen Lin; James K Liao
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

Review 4.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

Review 5.  Regulation of pulmonary endothelial barrier function by kinases.

Authors:  Nektarios Barabutis; Alexander Verin; John D Catravas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-23       Impact factor: 5.464

6.  Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice.

Authors:  Nada Sallam; Anat Fisher; Saeid Golbidi; Ismail Laher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-04       Impact factor: 3.000

7.  Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout.

Authors:  Lin Yao; Surabhi Chandra; Haroldo A Toque; Anil Bhatta; Modesto Rojas; Ruth B Caldwell; R William Caldwell
Journal:  Cardiovasc Res       Date:  2012-12-17       Impact factor: 10.787

8.  Rho-Kinase activity and cutaneous vasoconstriction is upregulated in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Lacy M Alexander
Journal:  Microvasc Res       Date:  2013-02-26       Impact factor: 3.514

9.  Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.

Authors:  Karla K V Haack; Lie Gao; Alicia M Schiller; Pamela L Curry; Peter R Pellegrino; Irving H Zucker
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

Review 10.  Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?

Authors:  James K Liao
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.